Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute lymphoblastic leukaemia patients

Bookmark and Share
Published: 22 Dec 2020
Views: 467
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA

Prof Kantarjian speaks to ecancer about a study presented at ASH 2020 regarding a phase 2 trial; long-term follow-up of the combination of low-intensity chemotherapy plus inotuzumab ozogamicin with or without blinatumomab in patients with relapsed-refractory Philadelphia chromosome-negative acute lymphoblastic leukaemia.

He says that the outcome of patients with relapsed-refractory (R/R) acute lymphoblastic leukaemia (ALL) is poor.

Inotuzumab ozogamicin and blinatumomab are highly active single agents in R/R ALL. The combination of inotuzumab with low-intensity mini-hyper-CVD chemotherapy showed encouraging results in this patient population.

The sequential addition of blinatumomab optimises the efficacy of the regimen, reduce its toxicities, and further improve outcomes in R/R ALL.

He says that the aim of the analysis was to evaluate the efficacy and safety of inotuzumab ozogamicin plus low-intensity chemotherapy with or without blinatumomab in R/R ALL.

Prof Kantarjian then explains the key results from this study and how they can impact the future treatment of Ph- ALL.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute lymphoblastic leukaemia patients

Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA

I’d like to discuss a bit of a study we reviewed at ASH and this is the study concerning the low dose intensity chemotherapy with mini-CVD in combination with blinatumomab and inotuzumab in the setting of ALL refractory relapse, meaning salvage one and beyond. So this is a study that we published before and now we have the long-term follow-up. We have 96 patients that we treated with the combination of mini-CVD, inotuzumab blinatumomab. What we have reported is that we can achieve a very high complete response rate and very good survival in a population where the disease was invariably fatal. So if you look at the historical data of patients, for adults with acute lymphoblastic leukaemia who relapse, then achieve a complete remission rate of 30-40% with intensive chemotherapy and their median survival is about 6 months and at two years almost nobody is alive, even with the availability of allogeneic transplant.

In this study what we show is that of 64 patients who were in salvage one, the CR rate was 91% and the MRD negativity was 89%. In the setting of salvage two and three, the CR rate was 55-60% and the MRD negativity rate was 63%. When we compared the data of the mini-CVD, ino-blinatumomab, to single agent therapy such as blinatumomab or inotuzumab we have observed that we can improve the estimated four year survival from less than 20% to about 30%. When we look at patients in salvage one, the estimated five year survival was close to 35% which is unheard of. It is a really important breakthrough.

In patients in salvage two and beyond the estimated two year survival rate is close to 20% which is as good as we get with CAR T-cell therapy. Then we reported that patients who achieved MRD negativity do the best and that allogeneic stem cell transplantation is needed.

Now, let’s put this into the context of the total ALL therapy because now we are undergoing a therapeutic revolution in ALL. I hope that five years from now we will not be talking about a cure rate of 50% in adult ALL and the need for three years of intensive chemotherapy. I think the future is going to be the possibility of a potential cure rate, or at least an estimated five-year survival rate, of 70-80%, very close to the cure rates in paediatric ALL. The treatment is going to be with much less chemotherapy and with a shorter duration of treatment that incorporates antibody cocktails including inotuzumab and blinatumomab.

Finally, I’d like to draw attention to an abstract at ASH discussing MRD status. This is abstract 583 and this discusses detection of minimal residual disease at the level of 10-6 and demonstrating that patients who achieve MRD negativity at the level of 10-6 are not relapsing. So in the future perhaps this will be an endpoint of therapy to decide on the duration of the treatment in patients with adult acute lymphoblastic leukaemia and hopefully also in the future this will spill over to paediatric leukaemias where we will need much less of the intensity and the duration of the chemotherapy which will be replaced by antibody cocktails.